Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocetinostat and Vinorelbine in Refractory/Recurrent Rhabdomyosarcoma
NCT04299113Phase 1Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2020
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mocetinostat in rhabdomyosarcoma (RMS), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Dose-Limiting Toxicity at 1 year and Maximum Tolerated Dose at 1 year. Started May 2020; status: active, not recruiting.
02
Drugs
mocetinostat
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT04299113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04299113.